Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
Sarepta Therapeutics (NASDAQ:SRPT) announced that its senior management will participate in a fireside chat during the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022, at 2:15 p.m. E.T.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sarepta Therapeutics (NASDAQ:SRPT) announced that its senior management will participate in a fireside chat during the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022, at 2:15 p.m. E.T. The event will be held virtually and available for live streaming on the investor relations section of Sarepta's website. The presentation will remain archived for 90 days post-event. Sarepta is dedicated to developing precision genetic medicine for rare diseases, with over 40 programs in development.
Details
News Market Reaction – SRPT
The recorded move for SRPT in the trading session of this news was +2.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 2:15 p.m. E.T. The fireside chat will be held virtually.
The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.